C57BL/6-Gt(ROSA)26tm1(SIGLEC8)Bcgen/Bcgen • 111149
| Product name | B-hSIGLEC8 mice |
|---|---|
| Catalog number | 111149 |
| Strain name | C57BL/6-Gt(ROSA)26tm1(SIGLEC8)Bcgen/Bcgen |
| Strain background | C57BL/6 |
| Aliases | SAF2; SIGLEC-8; SIGLEC8L |
Targeting strategyGene targeting strategy for B-hSIGLEC8 mice. The BAC containing the whole sequence of human SIGLEC8 gene was inserted into Rosa26 locus in B-hSIGLEC8 mice.
Protein expression analysis
SIGLEC8 expression analysis in homozygous B-hSIGLEC8 mice by flow cytometry. Blood and Peritoneal lavage fluid were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hSIGLEC8 mice (H/H), and analyzed by FACS with anti-SIGLEC8 antibody. Human SIGLEC8 was detectable in Eosinophils(88%, mSiglec-F+,mCD11c-) and mast cells (99.8%, mFcεRIα+,mCD117(c-kit)+,CD11b-) in homozygous B-hSIGLEC8 mice.
Eosinophils and mast cells in B-hSIGLEC8 mice bind to anti-human SIGLEC8 antibody
Analysis of eosinophils and mast cells of B-hSIGLEC8 mice by flow cytometry. Eosinophils and Peritoneal lavage-mast cells isolated from wild-type C57BL/6 mice (+/+) and B-hSIGLEC8 mice (H/H). Flow cytometry analysis was performed to assess human SIGLEC8 expression using the Benchmark antibody Lirentelimab (in house). Eosinophils were gated from mSiglec-F+, mCD11c- population and mast cells were gated from CD45+mFcεRIα+, mCD117(c-kit)+CD11b- population. Lirentelimab was exclusively binding to SIGLEC8 in homozygous B-hSIGLEC8 mice but not wild-type mice.
The number of BALF immune cells in mouse asthma model
In vivo efficacy of anti-human SIGLEC8 antibody
H&E staining in asthma-like model in B-hSIGLEC8 mice. (A) Lung tissues were collected from at the study end point. H&E staining results showed that the lung tissues from B-hSIGLEC8 mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammation in B-hSIGLEC8 mice. (B) A significantly reduction in eosinophils infiltration was observed in mice treated with lirentelimab (in house).
Note: The lirentelimab in the treatment model group were administered via intratracheal aerosolization.
